Back to Main

Faculty Detail    
Name UPENDER MANNE
 
Campus Address WTI 420A Zip 3300
Phone  205-934-4276
E-mail  manne@uab.edu
Other websites Google Scholar
Research Gate
     


Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Pathology   Anatomic Pathology Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor
Center  General Clinical Research Center  Minority Health & Research Center Professor

Graduate Biomedical Sciences Affiliations
Cancer Biology 
Integrative Biomedical Sciences 
Medical Scientist Training Program 
Molecular and Cellular Pathology Program 
Pathobiology and Molecular Medicine 

Biographical Sketch 
Dr. Manne obtained his M.S. (Biochemistry, Histochemistry, Parasitology, Zoonosis) and Ph.D. (energy metabolic pathways of endoparasites) degrees from Osmania University, Hyderabad, India. His postdoctoral training was in molecular immunology and vaccine development for malaria (Malaria Research Center, Delhi, India); in helicobacter infections (School of Microbiology, University of New South Wales, Sydney, Australia); and in histopathology, molecular tumor biology, and preclinical translational research of human malignancies at the University of Alabama at Birmingham (UAB). He also received certification in bioinformatics at UAB.

Dr. Manne’s research on racial disparity in CRC has received considerable national and international recognition. In 2009, the Presidents Cancer Panel invited Dr. Manne to speak on “Biologic differences between ethnic groups and their clinical implications in cancer care,” and devoted to the topic, “America’s demographic and cultural transformation: implications for the cancer enterprise.” Currently, he is the Lead Principal Investigator of a Comprehensive Partnership between UAB Comprehensive Cancer Center and Tuskegee University, Tuskegee, AL and Morehouse School of Medicine, Atlanta, GA, to Reduce Cancer Health Disparities (U54), funded by the National Cancer Institute of the National Institute of Health.

Society Memberships
Organization Name Position Held Org Link
American Association for Cancer Research  Active member   
American Society of Clinical Oncology  Active member   

Research/Clinical Interest
Title
Translational research in grastrointestinal malignancies and breast cancer
Description
Dr. Manne’s present efforts are focused on population-based translational research for human neoplasias, with emphasis on colorectal and breast cancers. His laboratory, with projects funded by the National Cancer Institute and the Susan G. Komen Foundation, is evaluating molecular markers to identify aggressive phenotypic features of tumors to predict the efficacy of chemotherapeutic regimens and to assess clinical outcomes. Dr. Manne’s research and collaborative groups include experts in the fields of molecular biology, clinical oncology, pathology, epidemiology, statistics, and bioinformatics. For evaluating the clinical utility of genetic and phenotypic abnormalities in colorectal cancer, his group has developed strategies demonstrating that the utility of molecular biomarkers varies according to the anatomic location of tumors within the colorectum and with tumor stage, race/ethnicity, age, and gender. To validate the clinical utility of genetic and phenotypic markers, Dr. Manne’s laboratory is evaluating hundreds of colorectal cancer samples derived from African American and non-Hispanic Caucasian ethnic/racial backgrounds and collected from different institutions. Established molecular markers with be merged with other epidemiological, environmental, and socio-economic features to find the basis for racial disparities in colorectal and breast malignancies. Results from approaches involving biomarker discovery and bioinformatics will aid in developing predictive models specific for individual patients. The research interests of Dr. Manne also include use of genomics and proteomics for identification of early markers of cancers, specifically, identification of molecular signatures of benign colonic epithelium, which is at risk of developing colorectal neoplasias, and of other pre-malignant lesions. These studies will aid in the evaluation of molecular and pathologic characteristics of specimens and in the development of assays that relate to early detection, diagnosis, prognosis, and treatment of cancers.

Selected Publications 
Publication PUBMEDID
Kumar S, Stokes J 3rd, Singh UP, Scissum Gunn K, Acharya A, Manne U, Mishra M. Targeting Hsp70: A possible therapy for cancer.Cancer Lett. 2016;374(1):156-66.  26898980 
Krishna SR, Kaur S, Smith LM, Johansson SL, Jain M, Patel A, Gautam SK, Hollingsworth MA, Mandel U, Clausen H, Lo WC, Fan WL, Manne U, Batra SK. Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer. Cancer Lett. 2016. pii: S0304-3835(16)30070-2.  26898938 
Narayanan NK, Kunimasa K, Yamori Y, Mori M, Mori H, Nakamura K, Miller G, Manne U, Tiwari AK, Narayanan B. Antitumor activity of melinjo (Gnetum gnemon L.) seed extract in human and murine tumor models in vitro and in a colon-26 tumor-bearing mouse model in vivo.Cancer Med. 2015;4(11):1767-80.   26408414 
Katkoori VR, Basson MD, Bond VC, Manne U, Bumpers HL.Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.Oncotarget. 2015;6(29):27763-77.   6318034 
Fadlalla K, Elgendy R, Gilbreath E, Pondugula SR, Yehualaeshet T, Mansour M, Serbessa T, Manne U, Samuel T.3-(2-Bromoethyl)-indole inhibits the growth of cancer cells and NF-κB activation.Oncol Rep. 2015;34(1):495-503.  26063116  
Bumpers HL, Janagama DG, Manne U, Basson MD, Katkoori V.Nanomagnetic levitation three-dimensional cultures of breast and colorectal cancers.J Surg Res. 2015;194(2):319-26.  25617973 
Karthikeyan C, Lee C, Moore J, Mittal R, Suswam EA, Abbott KL, Pondugula SR, Manne U, Narayanan NK, Trivedi P, Tiwari AK. IND-2, a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells.Bioorg Med Chem. 2015;23(3):602-11.  25537531 
Putcha BD, Jia X, Katkoori VR, Salih C, Shanmugam C, Jadhav T, Bovell LC, Behring MP, Callens T, Messiaen L, Bae S, Grizzle WE, Singh KP, Manne U.Clinical Implications of Rabphillin-3A-Like Gene Alterations in Breast Cancer.PLoS One. 2015 12;10(6):e0129216.   26070152 
Samuel T, Fadlalla K, Gales DN, Putcha BD, Manne U.Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs.BMC Cancer. 2014 Aug 18;14:599.   25134433 
Tabatabai MA, Kengwoung-Keumo JJ, Eby WM, Bae S, Manne U, Fouad M, Singh KP.A New Robust Method for Nonlinear Regression. J Biom Biostat. 2014;5(5):211  26185732 
Tabatabai MA, Li H, Eby WM, Kengwoung-Keumo JJ, Manne U, Bae S, Fouad M, Singh KP.Robust Logistic and Probit Methods for Binary and Multinomial Regression.J Biom Biostat. 2014;5(4). pii: 202.  26078914  
Tabatabai MA, Kengwoung-Keumo JJ, Eby WM, Bae S, Guemmegne JT, Manne U, Fouad M, Partridge EE, Singh KP.Disparities in cervical cancer mortality rates as determined by the longitudinal hyperbolastic mixed-effects type II model.PLoS One. 2014;9(9):e107242.   25226583  
McNally L, Manne U, Grizzle WE.Post-transcriptional processing of genetic information and its relation to cancer.Biotech Histochem. 2013;88(7):365-72.  23286224 
Doidge C, Crust I, Lee A, Buck F, Hazell S, Manne U: Therapeutic immunisation against helicobacter infection. LANCET,1994; 343 (8902):914-5.  7908372 
Manne U, Myers RB, Srivastava S, Grizzle WE. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J. NATL. CANCER. INST., 1997; 89(8): 585-6.  9106651 
Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss HL, Brown D, Srivastava S, Grizzle WE. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. INT. J. CANCER, 1997;74(3): 346-58.  9221816 
Manne U, Weiss HL, Myers RB, Danner OK, Moron C, Srivastava S, Grizzle WE. Nuclear accumulation of p53 in colorectal adenocarcinoma: prognostic significance differs with race and location of the tumor. CANCER, 1998; 83(12): 2456-67.  9874449 
Myers RB, Oelschlager DK, Coan PN, Frost AR, Weiss HL, Manne U, Pretlow TG, Grizzle WE.
J Urol. 1999 Mar;161(3):945-9.Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma.J Urol. 1999 Mar;161(3):945-9. 
10022731 
Urban D, Myers R, Manne U, Weiss H, Mohler J, Perkins D, Markiewicz M, Lieberman R, Kelloff G, Marshall M, Grizzle W.Evaluation of biomarker modulation by fenretinide in prostate cancer patients.Eur Urol. 1999;35(5-6):429-38.  10325501 
Myers RB, Oelschlager D, Manne U, Coan PN, Weiss H, Grizzle WE.Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma. Int J Cancer. 1999 Jul 30;82(3):424-9.  10399960 
Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG, Grizzle WE.Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.J Urol. 1999 Oct;162(4):1462-6.  10492238 
Piyathilake CJ, Frost AR, Weiss H, Manne U, Heimburger DC, Grizzle WE.The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung.Hum Pathol. 2000 Apr;31(4):482-7.  10821496 
Piyathilake CJ, Frost AR, Manne U, Bell WC, Weiss H, Heimburger DC, Grizzle WE.The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung.Hum Pathol. 2000 Sep;31(9):1068-73.  11014573 
Manne U, Weiss HL, Grizzle WE. Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas. INT. J. CANCER, 2000; 89(5): 423-30.  11008204 
Piyathilake CJ, Johanning GL, Frost AR, Whiteside MA, Manne U, Grizzle WE, Heimburger DC, Niveleau A.Immunohistochemical evaluation of global DNA methylation: comparison with in vitro radiolabeled methyl incorporation assay.Biotech Histochem. 2000 Nov;75(6):251-8.  11131565 
Manne U, Weiss HL, Grizzle WE. Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas. CLIN.CANCER RES. 6(10):4017-25, 2000.   11051251  
Grizzle WE, Manne U, Jhala NC, Weiss HL. Molecular characterization of colorectal neoplasia in translational research. ARCH. PATHOL.LAB. MED.,2001; 125(1): 91-8(Review).  11151060 
Gibbons MD, Manne U, Carroll WR, Peters GE, Weiss HL, Grizzle WE.Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope. 2001 Aug;111(8):1373-8.  11568571 
Manne U, Gary BD, Oelschlager DK, Weiss HL, Frost AR, Grizzle WE. Altered subcellular localization of suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomas. CLIN. CANCER RES., 2001; 7(11): 3495-503.  11705868 
Grizzle WE, Manne U, Weiss HL, Jhala NC, Talley L. Molecular staging of coloretal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2 MUC1 and p27kip-1. INT. J. CANCER.,2002; 97(4): 403-9 (Review).  11802199 
Miller CR, Gustin AN, Buchsbaum DJ, Vickers SM, Manne U, Grizzle WE, Cloud GA, Diasio RB, Johnson MR.Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: a sensitive method for assessing 5-fluorocytosine toxicity in vitro. Anal Biochem. 2002 Feb 15;301(2):189-99.  11814289 
Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Heimburger DC, Grizzle WE.Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res. 2002 Mar;8(3):734-44.  11895903 
Piyathilake CJ, Frost AR, Manne U, Weiss H, Heimburger DC, Grizzle WE.Nuclear accumulation of p53 is a potential marker for the development of squamous cell lung cancer in smokers.Chest. 2003 Jan;123(1):181-6.  12527620 
TAlvarez RD, Conner MG, Weiss H, Klug PM, Niwas S, Manne U, Bacus J, Kagan V, Sexton KC, Grubbs CJ, Eltoum IE, Grizzle WE. The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial.Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):114-9.  12582020 
Chhieng DC, Benson E, Eltoum I, Eloubeidi MA, Jhala NC, Jhala D, Siegal GP, Grizzle WE, Manne U. MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. CANCER., 2003; 99(6): 635-71.   14681945 
Manne U, Jhala NC, Jones J, Weiss HL, Chatla C, Meleth S. Suarez-Cuervo C, Grizzle WE. Prognostic significance of p27kip-1 expression in colorectal adenocarcinomas is associated with tumor stage. CLIN. CANCER RES.,2004; 10(5):1743-52.  15014027  
Alexander D, Chatla C, Funkhouser E, Meleth S, Grizzle WE, Manne U.Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma. Cancer. 2004 Jul 1;101(1):66-76.
 
15221990  
Manne U, Alexander D, Chatla C. Re: Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma.
Cancer. 2004 Dec 15;101(12):2900.  
15494973 
Alexander D, Nirag Jhala, Chatla C, Funkhouser E, Coffey C, Grizzle WE, Manne U. High grade tumor differentiation is a poor prognostic indicator of African Americans with colonic adenocarcinomas. Cancer 2005, 103:2163-2170.  15816050  
Manne U, Srivastava RG, Srivastava S. Keynote review: Recent advances in biomarker application in cancer diagnosis and treatment. Drug Discovery Today 2005, 10: 965-976.  16023055 
Chatla C, Jhala NC, Katkoori VR, Alexander D, Meleth S, Grizzle WE, Manne U. Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma. Cancer Biomarkers 2005, 1:241-250.   17192048 
Grizzle WE, Semmes OJ, Bigbee W, Zhu L, Malik G, Oelschlager DK, Manne B, Manne U.The need for review and understanding of SELDI/MALDI mass spectroscopy data prior to analysis.Cancer Inform., 2005;1:86-97.  19305634 
Grizzle WE, Semmes OJ, Bigbee W, Zhu L, Malik G, Oelschlager DK, Manne B, Manne U.The need for review and understanding of SELDI/MALDI mass spectroscopy data prior to analysis.Cancer Inform. 2005;1:86-97.  19305634 
Baker AC, Eltoum I, Curry RO, Stockard CR, Manne U, Grizzle WE, Chhieng D.Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix.Arch Pathol Lab Med. 2006 Oct;130(10):1510-5.  17090193 
Jhala N, Jhala D, Vickers SM, Eltoum I, Batra SK, Manne U, Eloubeidi M, Jones JJ, Grizzle WE. Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates.
Am J Clin Pathol. 2006 Oct;126(4):572-9.
 
17019794  
Verma M, Manne U. Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. Crit Rev Oncol Hematol. 2006 Oct;60(1):9-18. 2006 Jul 10. Review.  16829121 
Benavides MA, Oelschlager DK, Zhang HG, Stockard CR, Vital-Reyes VS, Katkoori VR, Manne U, Wang W, Bland KI, Grizzle WE. Methionine inhibits cellular growth dependent on the p53 status of cells. Am J Surg. 2007 Feb;193(2):274-83.
 
17236862 
Manne U. Understanding racial differences in colorectal cancer aids in individualized medicine. Future Oncol., 2007 Jun;3(3):235-41.  17547516 
Alexander DD, Waterbor J, Hughes T, Funkhouser E, Grizzle W, Manne U.African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: an epidemiologic review.Cancer Biomark. 2007;3(6):301-13.   18048968 
Chhieng D, Hardin M, Anderson B, Manne U. Predicting 5-year survival of colorectal carcinoma patients using data mining methods. AMIA Proc. 2007 Oct 11:907.  18694007 

Keywords
Colorectal Cancer, Breast Cancer, Molecular Biomarkers, Racial/Ethnic Disparities, Cancer Control & Prevention